Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized by the selective degeneration of upper and lower motor neurons. The lack of a molecular diagnostic marker is of increasing concern in view of the therapeutic strategies in development. Using an unbiased subtractive suppressive hybridization screen we have identified a clone encoding the neurite outgrowth inhibitor Nogo and shown that its isoforms display a characteristic altered expression in ALS. This was first confirmed by analyzing Nogo isoform expression in a transgenic ALS model at early asymptomatic stages where we found increased levels of Nogo-A and decreased Nogo-C and importantly, not following experimentally induced denervation. Furthermore, we confirmed these changes in both post-mortem and biopsy samples from diagnosed ALS patients but not control patients. Thus, the alteration in Nogo expression pattern, common to sporadic and familial ALS, represents a potential diagnosis tool and points strongly to Nogo having a central role in disease.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive and selective loss of motor neurons in the spinal cord, brainstem, and motor cortex. Clinical features include limb weakness with muscle atrophy and a progressive involvement of respiratory muscles leading to death within 3 to 5 years after the onset (Brooks, 1994) . Several mechanisms have been postulated to explain motor neuron degeneration, including oxidative stress, glutamate excitotoxicity and apoptosis, which suggest that the disease is multifactorial in origin (Eisen, 1995) . However, the precise molecular mechanisms responsible for the selective loss of motor neurons remain obscure. Five to 10% of ALS cases are dominantly inherited, and genetic linkage studies revealed that 20% of these are associated with point mutations in the gene encoding cytosolic Cu/Zn superoxide dismutase (SOD1) (Rosen et al., 1993) , a free radical scavenging enzyme that protects cells against oxidative stress (Fridovich, 1986) . It has been demonstrated that the deleterious mechanism of these mutations is related to a gain of function (Brown, 1995) . The identification of such mutations has allowed the production of transgenic mice that develop neurological disorders characteristic of ALS (Gurney et al., 1994; Ripps et al., 1995; Wong et al., 1995) .
In man, sporadic and familial ALS are clinically and pathologically similar, suggesting a common pathogenesis (Ince et al., 1998) . No treatment has yet proved to stop the course of the disease. However, it has been 
